HARBINGER STRATEGIES, LLC

Lobbying for CSL BEHRING LLC · Biopharmaceutical company

Filing 4th Quarter - Termination

4th Quarter (Oct 1 - Dec 31) 2025 · Pennsylvania · House · Senate · $50,000.00 income · posted Jan 20, 2026

Bills named in this filing 2

Lobbying activity 1

Health Issues

The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.